Inactive Instrument

News Kancera AB Nasdaq Stockholm

Equities

End-of-day quote Nasdaq Stockholm Other stock markets
- ^SEK	-

05-16	Kancera AB Provides Operational Update Regarding the Kandova Study and Reports Increased Patient Recruitment	CI
05-08	Kancera AB Announces Executive Changes	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Kancera - Underestimated optionality	05-22	AQ
Interim Report First Quarter 2024, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851	05-17	AQ
Kancera provides operational update regarding the KANDOVA study and reports increased patient recruitment	05-16	AQ
Kancera AB Provides Operational Update Regarding the Kandova Study and Reports Increased Patient Recruitment	05-16	CI
Kancera appoints new Chief Scientific Officer and extends management team	05-08	AQ
Kancera AB Announces Executive Changes	05-08	CI
Kancera meets the primary objectives of the KAND145 clinical phase I study	05-03	AQ
Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects	05-03	CI
Kancera announces the outcome of the company's rights issue	03-20	AQ
Kancera publishes prospectus in connection with the company’s rights issue	03-01	AQ
Kancera resolves on a rights issue of approximately SEK 121.9 million	02-23	AQ
Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851	02-23	AQ
Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study	02-23	AQ
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Kancera AB Signs A License Agreement with the University of Newcastle	02-23	CI
Kancera AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-22	CI
Kancera presents the statistical analysis of top line data from the FRACTAL study	02-06	AQ
Kancera AB Presents the statistical Analysis of Top Line Data from the FRACTAL Study	02-06	CI
Kancera reports positive top line results from the FRACTAL study	12-20	AQ
Kancera AB Reports Positive Top Line Results from the FRACTAL Study	12-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kancera AB Nasdaq Stockholm

Equities

Summary

Filters